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1. Introduction 
Insomnia is the most prevalent sleep disorder; especially in the elderly.1-3 It is diagnosed in 
women (55-60%) more often than men (40-45%).4-6 It can occur acutely (as known as 
transient insomnia) or become a chronic disorder (occurring at least three or more times per 
week, usually one to six months in duration and with some degree of daytime dysfunction).4 
Epidemiological studies indicate that at least one symptom of insomnia occurs in 
approximately one-third of the adult population with about 10 to 15 percent of these cases 
suffering from chronic insomnia with daytime consequences lasting for months or for many, 
years.4-10  
Chronic insomnia is frequently associated with depression and other psychiatric disorders 
including generalized anxiety disorder (GAD).11-14 For some patients, insomnia symptoms 
may be a predictor for the onset of clinical depression.12-16 Thus, given the potential for 
insomnia or its symptoms to reflect and/or trigger the onset of concomitant disease states, a 
thorough diagnostic examination is warranted in these patients. 
Treatment guidelines for insomnia patients with comorbid mental illness are aimed at 
addressing the underlying psychiatric problem in order to improve sleep disturbances.5,13 
Successful treatment can only be achieved by a thorough understanding of the extent of the 
problem and the proper choice of interventions. A combination of lifestyle changes, 
psychiatric, complementary and alternative medicine, as well as pharmacotherapy are often 
employed to achieve a positive and lasting outcome.  
2. Psychiatric comorbidities 
The connection between insomnia and psychiatric comorbidities can be attributed to more 
than a simple cause and effect relationship. A bidirectional relationship has been identified 
in the literature.17,18 Researchers have also determined that patients diagnosed with severe 
insomnia are 6 times more likely to have had a prior mental illness.14 One study found that 
the odds of having at least one psychiatric diagnosis was 5.04 times greater in patients with 
severe insomnia as compared to those without insomnia and that increasing insomnia 
severity was associated with increased chronic medical and psychiatric illnesses. 19 
Moreover, insomnia has been confirmed as a risk factor for future mental illness.18  
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3. Anxiety and depression 
A prospective study conducted in Sweden showed that both anxiety and depression were 
associated with future insomnia and insomnia was associated with future anxiety and 
depression.17 A baseline diagnosis of anxiety significantly predicted future insomnia, while 
an insomnia diagnosis at baseline significantly predicted future depression. A community-
based retrospective study identified that chronic insomnia sufferers were about 10 times 
more likely to have clinically significant depression and about 17 times more likely to have 
clinically significant anxiety.20 Chronic insomnia has been found to increase the risk of 
developing depression anywhere from 2 to 40 fold and those being treated for depression 
and have concomitant chronic insomnia are 2 to 4 times more likely to remain depressed if 
the insomnia remains untreated.21-23 
4. Generalized anxiety disorder 
The strong bidirectional association between chronic insomnia and anxiety disorders may 
indicate that they share an overlapping neurobiological abnormality with common 
symptoms and physiological markers (e.g. hyperarousal).24 It is estimated that 70 to 90% of 
anxiety patients have insomnia as a complaint.24,25 Two anxiety disorders, generalized 
anxiety disorder (GAD) and post traumatic stress disorder (PTSD) include sleep disturbance 
as part of the DSM-IV TR diagnostic criteria.  
GAD has the highest comorbidity rate with insomnia; exceeding the comorbid rate of 
depression and insomnia.11,25-27 Research estimates are as many as 50 to 70% of GAD 
sufferers have insomnia.26 Additionally, sleep disturbances seem to worsen or trigger GAD-
related symptoms of fatigue and irritability which are also hallmark consequences of 
insomnia.26-27 Other overlapping symptomatology include excessive worry, significant 
daytime impairment, decreased sleep efficiency, increased nocturnal awakenings, and rapid 
eye movement (REM) sleep disturbances.25,26 
5. Post traumatic stress disorder 
PTSD patients commonly (70-90%) experience sleep disturbances.26,27 These patients report 
sleep disturbance symptoms such as poor sleep quality, decreased total sleep time, 
nightmares, and hyerarousal.26,27 Of important note, is that research has not demonstrated a 
bidirectional relationship between insomnia and PTSD given that an intervening trauma is 
necessary to establish a diagnosis of PTSD. Insomnia may predict the development of PTSD 
after trauma exposure however, and patients with more severe insomnia symptoms within a 
month of the trauma incident are at greater risk of developing PTSD within the following 12 
month period.26 Moreover, the severity of insomnia appears to be correlated with PTSD 
severity.18  
6. Panic disorder 
Empirical evidence exists to support the association between insomnia and panic disorder 
with about 67% of panic patients reporting difficulty falling asleep and 77% with difficulty 
maintaining sleep.26,27 Approximately 44 to 77% of panic patients experience nocturnal panic 
attacks which have different pathology from those experienced during daylight hours.27 A 
degree of hyperarousal may also be present.25 
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7. Comorbidity treatment stategies 
Nearly 80% of patients diagnosed with major depressive disorder (MDD) have sleep 
disturbances with disturbed sleep and fatigue remaining after successful treatment of the 
mood disorder.21,23,24,28,30 Lingering insomnia following treatment of depression is associated 
with increased risk of relapse (more than 50% of cases).21,24,30 Therefore, insomnia is a 
significant independent predictor of future depression.14,22-24,29 Clinical sequelae of insomnia 
such as negative affect, fatigue, anhedonia, poor concentration, and irritability are also 
symptoms found in depression. As mentioned earlier, a bidirectional relationship between 
depression and insomnia exists thereby emphasizing the importance of treating the 
insomnia independent of the comorbid condition.24,28,31  
8. Treatment strategies 
Several treatment strategies are utilized, often in various combinations, for the treatment of 
insomnia. These include psychological and behavioral therapy (PBT), pharmacotherapy, 
over-the-counter (OTC) medications, herbal and dietary supplements, complementary and 
alternative medicine (CAM), mind-body and lifestyle interventions (Table 1).  
 
Lifestyle: sleep hygiene, weight control, low impact exercise, dietary (e.g. elimination of 
caffeine, nicotine, alcohol) 
OTC medications: Not recommended by AASM and NIH 
Herbal / Dietary supplements: melatonin (for changes in circadian rhythm, jet lag, shift 
work, or documented deficiency only); valerian (for acute treatment only) 
PBT: stimulus control, coping skills, relaxation training (e.g. progressive muscle relaxation, 
guided imagery, abdominal breathing), CBT-I, multi-component therapy, sleep restriction, 
paradoxical intension, biofeedback, grief management 
Mind and Body: yoga, meditation, mindfulness-based programs (MBSR, MBCT, MBT-I, 
MBRP), tai chi, acupuncture, acupressure 
Pharmacological: SSRI or SNRI, augmentation with sedating antidepressant (low dose), 
BzRA (for acute treatment only), or benzodiazepine (minimal use: for acute or “as needed” 
treatment of anxiety symptoms only), prazosin 
KEY: AASM = American Academy of Sleep Medicine; BzRA = benzodiazepine receptor agonist; CBT-I 
= cognitive behavioral therapy for insomnia; MBSR = mindfulness-based stress reduction; MBCT = 
mindfulness-based cognitive therapy; MBT-I = mindfulness based therapy for insomnia; MBRP = 
mindfulness-based relapse prevention; NIH = National Institutes of Health; OTC = over-the-counter; 
PBT Psychological and Behavioral Therapy; SNRI – serotonin norepinephrine receptor inhibitor; SSRI = 
selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant 
Table 1. Treatment Options for Insomnia with Co-Morbid Mental Illness 
Unfortunately, clinicians are not routinely probing the level of sleep difficulties in their 
patients other than a simple identification (yes or no) of sleep disturbance.32-38 Treatment 
seeking behavior for insomnia is based on disease severity, fatigue, daytime consequences and 
comorbidities.32-33 A study of primary care patients with insomnia determined that the 
principal motivator for seeking treatment after controlling for insomnia severity was found to 
be the negative impact on daytime functioning.32 A community based study identified that 
daytime fatigue and psychological distress were the main predictors of treatment seeking 
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behavior.5 Moreover, when patients seek treatment for their insomnia symptoms, health care 
providers (HCPs) are significantly more prone to prescribe pharmacotherapy than to refer 
patients for behavioral interventions.34 Additionally, HCPs are more likely to diagnose one or 
more of the comorbidities as opposed to insomnia; there is a greater probability of obtaining 
reimbursement for these diagnoses by insurance carriers.10,37,38 Thus, behavioral interventions 
which presume a diagnosis of insomnia remain underutilized.37 
9. Sleep hygiene 
A thorough evaluation of sleep hygiene is required at initial evaluation of all patients with 
sleeping difficulties. These simple and basic sleep practices offer a consistent routine to 
assist patients to return to a normal sleep schedule.34,38-40 Adherence to good sleep hygiene 
practices is imperative in establishing a stable baseline to work from in order to improve 
sleeping difficulties. Sleep hygiene counseling includes the following:  
 Follow a regular sleep pattern; go to bed and arise at about the same time each day. 
 Eliminate daytime naps. 
 Make the bedroom comfortable for sleeping by avoiding temperature extremes, noise 
and light. 
 Make sure the bed is comfortable. 
 Go to bed only when sleepy. 
 Engage in relaxing activities before bedtime. 
 Use the bed and bedroom only for sleep and sexual activities only. 
 If unable to fall asleep, do not become anxious. Leave the bedroom and participate in 
relaxing activities for 20 to 30 minutes. 
 If tense, practice relaxation exercises (e.g. deep breathing, meditation). 
 If hungry, eat a light snack, but avoid eating meals or large snacks immediately before 
bedtime. 
 Avoid using caffeine after noon. 
 Avoid using alcohol or nicotine later in the evening. 
Sleep hygiene is most effective when used in conjunction with other behavioral treatments. 
The overall goal is to decrease or eliminate sleep-reducing behaviors such as inconsistent 
sleep and wake cycle, daytime napping, clock monitoring, and exercising or consuming 
caffeine-containing beverages too close to bedtime.39 One barrier to the success of sleep 
hygiene, is patient’s perception that their compensatory behaviors of napping and drinking 
caffeinated beverages enable them to function during the day making them resistant to 
abandon these behaviors.40 It is therefore recommended that HCPs be persistent in 
communicating their expectations on the importance of maintaining good sleep hygiene 
habits. 
10. Over-the-counter remedies 
Self-help remedies are a major source of treatments for many patients with insomnia. The 
most frequently used include over-the-counter (OTC) antihistamines (10-25%), herbal 
supplements, alcohol (10-25%), caffeinated beverages, or a diet high in carbohydrates 
and/or sugars throughout the day to combat fatigue.5,41 None of these are suitable choices 
for the treatment of insomnia. Alcohol may reduce sleep-onset latency via its CNS 
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depressive effects but it also disrupts sleep architecture causing disruption in REM and slow 
wave sleep.42-44  
OTC antihistamines (e.g. diphenhydramine and doxylamine) are available for short term 
treatment of mild cases of insomnia only and should not be used for chronic insomnia. 
There is minimal evidence that these antihistamines are effective in improving sleep 
parameters but they may actually reduce sleep quality.42,43 While these agents may help 
with mild cases of acute insomnia, they are not without potential serious adverse effects 
including daytime drowsiness, dizziness, fatigue, headaches, vomiting, and anticholinergic 
properties (e.g. blurred vision, urinary retention, confusion).44-45 Moreover, the American 
Academy of Sleep Medicine (AASM) and the United States National Institutes of Health 
(NIH) both agree that there is insufficient evidence supporting the use of OTC 
antihistamines for the treatment of insomnia. This is of great concern as patients may 
experiment with various self-help remedies for a significant amount of time before 
consulting their HCP about their sleeping difficulties. 
Many herbal and dietary supplements are marketed directly to the consumer as sleep aids 
however, consistent scientific evidence supporting their use is very limited.42,44,46  Valerian 
and melatonin are the only supplements with sufficient research of adequate rigor 
evaluating their use in insomnia.46 Unfortunately, recent meta-analyses of randomized 
clinical trials (RTCs) for valerian as monotherapy, or in combination with other herbal 
supplements, did not find significant improvement in sleep quality or sleep latency.47,48 
Melatonin is a naturally occurring hormone that regulates sleep and circadian schedules. 
Research on melatonin’s usefulness for insomnia is mixed. It has been primarily useful in 
decreasing sleep latency (e.g. jet lag, shift work-related insomnia) with no significant impact 
on sleep maintenance or total sleep time.43-44 Additionally, melatonin has been associated 
with adverse effects such as residual fatigue, dizziness, headache, and irritability.43,44 
Therefore, it is not routinely recommended for treatment of chronic insomnia. 
11. Psychological and behavioral therapy  
PBT is considered first line treatment in chronic insomnia.44 Unfortunately, it is under-
utilized by practitioners even though there is significant evidence proving its effectiveness 
in chronic insomnia with or without comorbid illness.30,36,44,49-51 Behavioral modification may 
actually be more useful for insomnia sufferers with comorbid illness as these patients are 
often burdened with a multitude of medications that enhance their risk for medication-
related adverse effects, interactions, and/or dependency / addiction.37  
It is hypothesized that physiological and cognitive hyperarousal contribute to the 
development and chronicity of insomnia.44 Moreover, patients tend to develop problematic 
sleep hygiene practices such as remaining awake in bed for long periods of time which 
causes heightened anxiety and frustration about inability to sleep, increased efforts to sleep, 
wakefulness, negative expectations, and distorted attitudes about their insomnia and its 
consequences on their work/life. PBT is specifically targeted to address these perpetuating 
negative learned responses. The goal of PBT is to elicit a change in the patient’s belief 
system, through education and awareness, which enhances the patient’s sense of self-
efficacy concerning their insomnia management.44 
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Relaxation training is often utilized with CBT-I and involves the use of progressive muscle 
relaxation, guided imagery, or abdominal breathing in order to lower somatic and 
cognitive arousal states that interfere with sleep.  
Instructions: PRM training involves the methodical tensing and relaxing of different muscle 
groups throughout the body. Techniques are widely available in written and audio formats. 
Stimulus control is for the patient to establish a clear and positive association between the 
bed and sleep, as well as, creating a stable sleep-wake schedule. It is designed to eliminate 
the negative association between the bed and undesirable outcomes (e.g. wakefulness, 
frustration, worry) 
Instructions: Follow appropriate sleep hygiene 
CBT-I is a combination of cognitive therapy with behavioral interventions (e.g., stimulus 
control, sleep restriction) with or without relaxation therapy. Cognitive therapy uses a 
psychotherapeutic method to reconstruct cognitive pathways with positive and 
appropriate concepts about sleep and its effects. CBT-I works to change the patient’s 
overall beliefs and unrealistic expectations about sleep.  
Multi-component therapy [without cognitive therapy] is employed by a majority of 
practitioners. It uses various combinations of behavioral interventions (e.g. stimulus 
control, relaxation, sleep restriction) and sleep hygiene education. 
Sleep Restriction is used to improve sleep continuity by using sleep restriction to enhance 
sleep drive. The TIB to the TST is limited initially through the use of baseline sleep logs. As 
sleep drive increases and the window of sleep opportunity remains restricted with 
daytime napping prohibited, sleep becomes consolidated. As soon as sleep continuity 
significantly improves, TIB is slowly increased to provide adequate sleep time to feel 
rested during the day, while preserving the newly acquired sleep consolidation. 
Instructions: Patients should be cautioned that sleep restriction may create possible 
sleepiness and reduce cognition. Maintain sleep log and determine mean TST for a 1-2 
week baseline; Set bedtime and wake-up times to approximate mean TST to achieve > 85% 
SE (TST/TIB x 100) over 1 week; the goal is for the TIB (not < 5 hrs) to be about the TST; 
Make weekly adjustments for SE > 85% to 90% over 1 week, TIB is increased by 15-20 
minutes, for SE < 80%, TIB is decreased by 15-20 minutes; Repeat TIB adjustment every 
week until TST goal is achieved. 
Paradoxical intention is used to eliminate anxiety over sleep performance. It is a targeted 
cognitive therapy which trains the patient to confront the fear of staying awake and its 
potential effects. 
Biofeedback training is used to reduce somatic arousal. It trains the patient to control a 
selected physiologic variable through auditory or visual feedback. 
Sleep hygiene teaches the patient healthy lifestyles that improve sleep. It is used in 
conjunction with stimulus control, relaxation training, sleep restriction, and/or CBT-I. 
Instructions: include, but are not limited to, keeping a regular sleep wake cycle, healthy 
dietary choices, regular daytime exercise program, maintaining a quiet sleep environment, 
avoidance of daytime napping, caffeine, nicotine, alcohol, other stimulants, excessive 
fluids, or stimulating activities before bedtime. 
KEY: CBT-I = cognitive behavioral therapy for insomnia; PBT = psychological and behavioral therapy; 
SE = sleep efficiency; TIB = time in bed; TST = total sleep time. 
Table 2. Common PBT for Chronic Insomnia 
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There are a number of different psychological and behavioral therapies available to address 
these aberrant behaviors (Table 2).37,39,40,51-53 Standard therapies of stimulus control, relaxation 
training, and cognitive behavioral therapy for insomnia (CBT-I) with or without relaxation 
therapy are well supported in the scientific literature.42,39,40,52,53 CBT-I is the most common form 
of PBT for chronic insomnia. CBT-I is individualized and combines several behavioral / multi-
modal interventions. CBT-I usually includes stimulus control, sleep restriction, cognitive 
psychotherapy, light and dark exposure, sleep hygiene education, bedroom modification, 
relaxation training, and gradual tapering of hypnotic medications (when applicable).44 
12. Complementary and alternative medicine 
Pharmacotherapy and PBT interventions continue to be the mainstays of treatment for 
chronic insomnia patients with mental illness comorbidity. However, the use of 
complementary and alternative medicines (CAMs) has increased dramatically in the 21st 
century. CAMs (e.g. acupuncture, mindfulness-based stress reduction, yoga, meditation) are 
an integral part of the holistic medicine approach which aims to treat the “whole patient.”54 
Patients are expected to play an active role in their health when receiving CAMs which 
appeals to many chronic sufferers who have experienced ineffective relief from conventional 
medicine practices. CAMs are increasingly becoming part of mainstream medicine as more 
research on their effectiveness is published.54-60 
CAMs are more commonly used by those with psychiatric disorders especially patients with 
anxiety, depression and insomnia.61-63 CAMs have shown to improve sleep in 4.5% of 
insomnia patients translating to 1.6 million U.S. citizens.64 Herbal supplements or nutritional 
medicine, tai chi, and yoga are the most common CAMs utilized with 56% of patients 
reporting that CAMs were important in maintaining their health and 72% thought there was 
a significant improvement in their insomnia symptoms.64  
Supportive evidence for acupuncture and acupressure in the treatment of insomnia is now 
available.65-68 However, while acupuncture and acupressure may assist to improve sleep 
quality, the efficacy of these interventions was inconsistent between studies for many sleep 
parameters, including sleep onset latency, total sleep duration, and time to waking.65-68 A 
recent study using electroacupucture for chronic insomnias demonstrated beneficial effects 
on sleep quality which, as the authors stated, may be associated with valuable repair of 
sleep architecture, reconstructing sleep continuity, prolonging slow wave sleep time and 
rapid eye movement (REM) sleep time.57 Research using acupuncture and acupressure 
remains in progress and will hopefully demonstrate the full benefits as more rigorous 
studies are completed and published. 
Mindfulness-based programs (utilizing meditation with or without yoga) have emerged as 
novel approaches to behavior modification, stress / anxiety reduction, pain management, 
and relapse prevention. Historically, meditation has been used to regulate physical and 
mental health and for spiritual development. Mindfulness meditation is an outgrowth from 
a Buddhist practice called vipassana (“to see a special way”).69 Mindfulness-based meditation 
is surfacing in Western cultures as a beneficial approach to patient healing for many chronic 
conditions (e.g. insomnia, chronic back pain, fibromyalgia, cancer, psoriasis)70-73 This 
meditation technique fosters acute awareness of the present moment and the impermanent 
nature of things.74 The patient is thereby able to cultivate the ability to respond to stimuli in 
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a nonjudgmental way; allowing them to navigate their life in a manner that does not involve 
attachment to particular beliefs.74 This form of self-compassion is the mechanism for 
reducing negative emotional reactions, enhancing resilience, and promoting self-healing. 
There is a growing emphasis in applying mindfulness-based meditation in behavioral 
medicine. The first formal program, mindfulness-based stress reduction (MBSR) was created 
by Jon Kabat-Zinn over 2 decades ago and involves an 8-week program with an experiential 
component (formal mindfulness meditation) and group processing / support.75 The MBSR 
program teaches patients how to make appropriate lifestyle changes by incorporating 
mindfulness techniques into their day-to-day life and encourages them to maintain a regular 
meditation practice. Several mindfulness-based programs have been designed from MBSR 
and adapted to meet the needs of specific populations. Mindfulness-based cognitive therapy 
(MBCT) is a program with assists in prevention and relapse of depression among 
individuals with recurrent major depressive disorders (MDD). MBCT could therefore be of 
benefit to those with insomnia and comorbid depressive illness.76 Most recently, preliminary 
work on mindfulness-based therapy for insomnia (MBT-I) has been described as an effective 
treatment choice.58-60 Additionally, there are also a mindfulness-based relapse prevention 
(MBRP) programs for depression, craving, as well as, alcohol and substance abuse.77,78 
Low impact exercise, Tai chi and yoga are increasing in popularity as published research on 
mind-body interventions supports their use to improve sleep quality and reducing latency 
and insomnia severity.79-81 Not all of these studies recruited chronic insomnia patients. 
Therefore, more yoga research is needed to validate its benefit for insomnia. Mainstream 
CAM studies including homoeopathy, massage, and aromatherapy are lacking at this time. 
13. Pharmacotherapy  
Currently there are no established treatment algorithms for insomnia with comorbid mental 
illness. While research has established the linkages between insomnia and psychiatric 
comorbidities, there is limited to no data to guide HCPs other than the reported 
recommendation to treat comorbidities (e.g. depression, GAD, PSTD, panic) concurrently, at 
recommended therapeutic doses, and in concert with PBT, sleep hygiene, and CAMs.44  
Pharmacotherapy for comorbid insomnia can be effective, however, in improving targeted 
sleep parameters and improving symptoms of depression and anxiety disorders.44,82-85 As 
mentioned earlier, treatment should address the insomnia and the comorbid mental illness 
simultaneously. Therapeutic choices include: benzodiazepine receptor agonists, selective 
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine receptor antagonists 
(SNRIs), sedating antidepressants, anticonvulsants, and atypical antipsychotics.44 
Pharmacotherapy is not curative and therefore the best outcomes are realized when used in 
combination with other previous mentioned interventions (e.g. sleep hygiene, PBT, CAMs). 
Table 3 summarizes pharmacotherapy choices for insomnia with comorbid mental illness, as 
well as, various treatment considerations. 
14. Sedative / hypnotics 
While sedative hypnotic medications like eszopiclone, zolpidem, zaleplon, benzodiazepines 
(e.g. alprazolam, lorazepam, temazepam) have demonstrated efficacy for short-term treatment 
of insomnia, very little evidence exists to confirm their usefulness in chronic situations.44 
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Moreover, sedative hypnotics can produce residual sedation, memory and performance 
impairment, increased risk of falls and fractures, as well as, undesirable behaviors while 
sleeping (e.g. sleep walking, sleep driving, sleep talking).44 Triazolam, for example, has been 
associated with rebound anxiety and is no longer considered a first line hypnotic.44 Thus, these 
medications are best reserved for initial short-term therapy with the goal of little to no 
utilization once other interventions (e.g. antidepressant, PBT, sleep hygiene, CAMs) are 
successfully employed. Benzodiazepines, such as lorazepam, can be useful for immediate relief 
of breakthrough anxiety symptoms (e.g. panic attack) and prescribed on a limited “as needed” 
basis.44 Buccal or sublingual administration of benzodiazepines provides rapid response and is 
very useful for these intense anxiety situations. 
 
Medication Therapeutic Considerations 
BRAs: eszopiclone, 
zolpidem, zaleplon 
For short term treatment of insomnia only; no evidence of 
efficacy in chronic situations.  
BZDs: alprazolam, 
lorazepam, triazolam, 
temazepam 
Best reserved for initial short term treatment of insomnia 
symptoms with the goal of little to no utilization once other 
interventions (e.g. SSRI, SNRI, PBT, sleep hygiene, CAMs) are 
successfully employed. May be used on a limited “as needed” 
basis for immediate relief of breakthrough anxiety symptoms 
(i.e. panic attack). 
SSRIs: citalopram, 
escitalopram, fluoxetine, 
paroxetine, sertraline 
SNRIs: duloxetine, 
venlafaxine 
“First line” for comorbid depression and/or anxiety disorders. 
Higher doses are often needed for anxiety disorders than for 
depression. Selection of medication is guided by treatment 
history, side effect profile, interactions with other medications, 
and expense. Citalopram and escitalopram have lowest 
propensity to interact with other medications. 
Sedating Antidepressants:
amitriptyline, doxepin, 
mirtazapine, nefazodone, 
trazodone,  trimipramine 
Use in low doses only; best used in combination as 
augmentation to SSRI or SNRI for treatment of persistent 
insomnia symptoms after an adequate trial of other 
interventions (e.g. SSRI, SNRI, PBT, sleep hygiene, CAMs). 
Limited evidence for trazodone and nefazodone as 
augmentation in PTSD. Do not use as monotherapy (weak 
efficacy). 
Anticonvulsants: 
gabapentin, tiagavine 
Atypical Antipsychotics: 
olanzapine, quetiapine 
Generally not recommended; limited evidence to support 
their use for chronic insomnia. Atypical antipsychotics show 
some promise in the treatment of anxiety disorders but their 
side effect profile (e.g, weight gain, metabolic syndrome) and 
noncompliance continue to limit their use.  
Alpha Blocker: prazosin For treatment of sleep disturbances (nightmares, disturbing 
dreams, insomnia) in PTSD. Recommended by the AASM Best 
Practice Guide for treatment of PTSD-related nightmares. 
Key: AASM = American Academy of Sleep Medicine; BRA = benzodiazepine receptor agonist; BZD = 
benzodiazepine; CAM = complementary and alternative medicine; PBT = psychological and behavioral 
therapy; PTSD = post traumatic stress disorder; SNRI = serotonin and norepinephrine reuptake 
inhibitor; SSRI = selective serotonin reuptake inhibitor. 
Table 3. Pharmacotherapy Choices for Insomnia and Comorbid Mental Illness 
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15. Antidepressants  
Antidepressant (AD) medications, primarily SSRIs (e.g. citalopram, escitalopram, fluoxetine, 
paroxetine, sertraline) and SNRIs (e.g. duloxetine, venlafaxine), are first line for treatment of 
MDD, GAD, panic disorder, and PTSD.86-88 These agents may or may not be effective in 
completely alleviating sleep disturbances. Therefore, low dose sedating antidepressants 
such as mirtazapine, doxepin, amitriptyline, or trimipramine, may be considered as 
augmentation when insomnia complaints continue even with adequate dosing of the SSRI 
or SNRI.44 Moreover, low dose ADs are best used in combination with other antidepressant 
pharmacotherapy as their evidence for efficacy as monotherapy is rather weak.89-94 Selection 
is primarily guided by treatment history, side effect profile, medications interactions and 
expense.44 Elderly patients, for example, may not tolerate the anticholinergic side effects of 
trazadone, doxepin and amitriptyline. The weight gain associated with mirtazipine could be 
deleterious to diabetics, hyperlipidemics, or cardiovascular patients.  
16. Anticonvulsants and atypical antipsychotics 
Evidence to support the use of anticonvulsants (gabapentin, tiagabine) and atypical 
antipsychotics (quetiapine, olanzapine) for chronic insomnia is insufficient at this time.44 
Off-label use of these medications should not be recommended as they increase the potential 
for significant adverse effects (e.g. seizures with tigabine; weight gain and metabolic 
syndrome with quetiapine and olanzapine).44 Additionally, atypical antipsychotics have 
been evaluated as monotherapy or augmentation in the treatment of anxiety disorders with 
or without comorbid MDD, schizophrenia, or bipolar disorder.89 This recent critical 
evaluation of the available research confirmed that although atypical antipsychotics showed 
promising results in the treatment of anxiety disorders, their side effect profiles continue to 
limited their use.89 Atypical antipsychotic side effects were found to be a source of non-
compliance and resulted in premature discontinuation of treatment with higher dropout 
rates found in the majority of randomized clinical trials.89 
17. Nefazodone, trazodone, and prazosin for PTSD 
Nightmares and insomnia produce significant distress and daytime impairment in those 
with PTSD. There is limited evidence supporting the efficacy of nefazodone and trazodone 
augmentation in PTSD.89 The AASM Best Practice Guide describes “low grade to sparse” data 
supporting trazadone use in this population and recommends against the use of nefazodone 
for the treatment of nightmares.90 Fortunately, there is promising research using prazosin to 
treat sleep disturbances in PTSD.85,91-93 Prazosin is the only medication to receive a grade of 
“recommended” by the AASM Best Practice Guide for the treatment of PTSD-related night 
mares.90 
18. Conclusions and recommendations  
Successful treatment of insomnia with comorbid mental illness is dictated by individualized 
treatment regimens where all appropriate options are considered. Treatment of both the 
insomnia and comorbid condition is important in achieving the best outcomes. Several 
treatment strategies in various combinations are often employed including sleep hygiene, 
PBT, CAMs, and pharmacotherapy. Behavioral modifications may actually be more useful 
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for insomnia sufferers with comorbid illness as these patients are often burdened with a 
multitude of medications. Standard therapies of stimulus control, relaxation training, and 
CBT-I with or without insomnia are well supported in the literature. CAMs are commonly 
utilized in patients with anxiety, depression, and insomnia. Additionally, mindfulness-
based programs (MBSR, MBCT, MBT-I, MBRP) are promising interventions and appear to 
be appropriate. Research on low-impact exercise (e.g. Tai chi and yoga) is currently 
emerging but certainly may be a beneficial lifestyle intervention in this population.  
Selection of pharmacotherapy is based on a patient’s treatment history, side effect profile, 
potential medication-related interactions, and expense. There are no established medication-
related treatment algorithms for insomnia with comorbid mental illness. Sedative hypnotics 
have a limited role in these patients and are best reserved for initial short-term therapy with 
the goal of limited to no use after positive outcomes are demonstrated with other 
interventions. SSRIs and SNRIs are first line pharmacotherapy for MDD, GAD, panic 
disorder, and PTSD. SSRIs or SNRIs as monotherapy, however, may not be effective in 
completely alleviating the sleeping disturbances in these patients and augmentation therapy 
with sedating low-dose AD may be useful. The use of anticonvulsants and atypical 
antipsychotics in these patients is currently not well supported in the literature and the side 
effect profiles are problematic. Prazosin is now an AASM recommended medication for the 
treatment of sleep disorders associated with PTSD patients. 
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